Gibson Dunn Represented HealthCare Royalty and Blue Owl Capital in Acquisition of BridgeBio Pharma’s Royalty Interest in Bayer’s BEYONTTRA®

Firm News  |  July 3, 2025

Gibson Dunn advised HealthCare Royalty and Blue Owl Capital on their acquisition from BridgeBio Pharma of its royalty interest in Bayer’s BEYONTTRA® for $300 million.

BEYONTTRA® is approved in Europe for the treatment of patients with Transthyretin Amyloid Cardiomyopathy (ATTR CM), a rare, progressive heart disease. In exchange for the upfront payment, HealthCare Royalty and Blue Owl are entitled to 60% of royalties on the first $500 million of annual BEYONTTRA® net sales in Europe, with an initial cap of up to 1.45 times the purchase price.

Our corporate team included partners Todd Trattner, Ryan Murr, and Catie Sakurai. Partners Jin Hee Kim and Ryan Kim and associate Kali Jelen advised on finance, partner Jeff Krause advised on restructuring, and partner Pamela Endreny and associate Ryan Rott advised on tax.